Bayer wants to amend Xarelto patent at centre of Sandoz's invalidity claim

Bayer wants to amend Xarelto patent at centre of Sandoz’s invalidity claim

Intellectual Property 2022-07-15 11:37 am By Christine Caulfield

Please login to bookmark

German pharmaceutical giant Bayer, which is facing a legal bid by generic drug maker Sandoz to invalidate patents covering blood clot drug Xarelto, is seeking to amend one of the patents in dispute.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au